Predictors for Developing Severe Myalgic Encephalomyelitis/Chronic Fatigue Syndrome following Infectious Mononucleosis
Leonard A Jason1*, Joseph Cotler1, Mohammed F Islam1, Jacob Furst2, Ben Z Katz3
1Center for Community Research, DePaul University, Chicago, IL 60614, USA. Emails: Leonard Jason: ljason@depaul.edu; Joseph Cotler: joey.cotler@gmail.com; Mohammed Islam: mfislam87@gmail.com;
2The College of Computing and Digital Media, DePaul University, Chicago, IL 60614, USA. Email: Jacob Furst: jfurst@cdm.depaul.edu;
3Northwestern University Feinberg School of Medicine, Department of Pediatrics, Chicago, 60611 USA. Email: Ben Z Katz: bkatz@northwestern.edu;
Background: About 10% of individuals who contract infectious mononucleosis (IM) have symptoms 6 months later that meet criteria for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Our study for the first time examined whether it is possible to predict who will develop ME/CFS following IM.
Methods: We have reported on a prospectively recruited cohort of 4,501 college students, of which 238 (5.3%) developed IM. Those who developed IM were followed-up at six months to determine whether they recovered or met criteria for ME/CFS. The present study focuses on 48 students who after six months had a diagnosis of ME/CFS, and a matched control group of 58 students who had no further symptoms after their IM. All of these 106 students had data at baseline (at least 6 weeks prior to the development of IM), when experiencing IM, and 6 months following IM. Of those who did not recover from IM, there were two groups: 30 were classified as ME/CFS and 18 were classified as severe ME/CFS. We measured the results of 7 questionnaires, physical examination findings, the severity of mononucleosis and cytokine analyses at baseline (pre-illness) and at the time of IM. We examined predictors (e.g., pre-illness variables as well as variables at onset of IM) of those who developed ME/CFS and severe ME/CFS following IM.
Results: From analyses using receiver operating characteristic statistics, the students who had had severe gastrointestinal symptoms of stomach pain, bloating, and an irritable bowel at baseline and who also had abnormally low levels of the immune markers IL-13 and/or IL-5 at baseline, as well as severe gastrointestinal symptoms when then contracted IM, were found to have a nearly 80% chance of having severe ME/CFS persisting six months following IM.
Conclusions: Our findings are consistent with emerging literature that gastrointestinal distress and autonomic symptoms, along with several immune markers, may be implicated in the development of severe ME/CFS.
DOI: 10.29245/2767-5122/2021/1.1129 View / Download Pdf